A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
allow manufacturers and sponsors of a drug to use alter-
native testing methods to animal testing to investigate 
the safety and effectiveness of a drug, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘FDA Modernization 
4
Act of 2021’’. 
5
21:58 May 28, 2021
H2565
2 
•HR 2565 IH
SEC. 2. ANIMAL TESTING ALTERNATIVES. 
1
Section 505 of the Federal Food, Drug, and Cosmetic 
2
Act (21 U.S.C. 355) is amended— 
3
(1) in subsection (b)(5)(B)(i)(II), by striking 
4
‘‘animal’’ and inserting ‘‘nonclinical tests or stud-
5
ies’’; 
6
(2) in subsection (i)— 
7
(A) in paragraph (1)(A), by striking ‘‘(in-
8
cluding tests on animals)’’; and 
9
(B) in paragraph (2)(B), by striking ‘‘ani-
10
mal or human studies’’ and inserting ‘‘nonclin-
11
ical tests or studies’’; and 
12
(3) after subsection (y), by inserting the fol-
13
lowing: 
14
‘‘(z) NONCLINICAL TEST OR STUDY DEFINED.—For 
15
purposes of this section, the term ‘nonclinical test or 
16
study’ means a test or study that is most likely to predict 
17
human response based on scientific evidence and occurs 
18
before or during the clinical trial phase of the investigation 
19
of the safety and effectiveness of a drug. Such test or 
20
study may include the following: 
21
‘‘(1) Cell-based assays. 
22
‘‘(2) Organ chips and microphysiological sys-
23
tems. 
24
‘‘(3) Sophisticated computer modeling. 
25
‘‘(4) Other human biology-based test methods. 
26
21:58 May 28, 2021
H2565
3 
•HR 2565 IH
‘‘(5) Animal tests.’’. 
1
Æ 
21:58 May 28, 2021
H2565
